766 related articles for article (PubMed ID: 18199548)
21. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
22. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.
Pieh C; Agostini H; Buschbeck C; Krüger M; Schulte-Mönting J; Zirrgiebel U; Drevs J; Lagrèze WA
Br J Ophthalmol; 2008 May; 92(5):689-93. PubMed ID: 18408080
[TBL] [Abstract][Full Text] [Related]
23. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
Lacal PM; Ruffini F; Pagani E; D'Atri S
Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
[TBL] [Abstract][Full Text] [Related]
24. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
25. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
27. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
Jackson MW; Roberts JS; Heckford SE; Ricciardelli C; Stahl J; Choong C; Horsfall DJ; Tilley WD
Cancer Res; 2002 Feb; 62(3):854-9. PubMed ID: 11830543
[TBL] [Abstract][Full Text] [Related]
28. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
29. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
30. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP
Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
32. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
[TBL] [Abstract][Full Text] [Related]
33. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
Fukasawa M; Korc M
Clin Cancer Res; 2004 May; 10(10):3327-32. PubMed ID: 15161686
[TBL] [Abstract][Full Text] [Related]
35. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis.
Ahmad S; Ahmed A
Endothelium; 2005; 12(1-2):89-95. PubMed ID: 16036320
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
38. Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia.
Stachon A; Aweimer A; Stachon T; Tannapfel A; Thoms S; Ubrig B; Köller M; Krieg M; Truss MC
Growth Factors; 2009 Apr; 27(2):71-8. PubMed ID: 19199116
[TBL] [Abstract][Full Text] [Related]
39. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
Lamszus K; Ulbricht U; Matschke J; Brockmann MA; Fillbrandt R; Westphal M
Clin Cancer Res; 2003 Apr; 9(4):1399-405. PubMed ID: 12684411
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
